22 Oct A first-in-human study of Tenalisib in patients with R/R hematologic malignancies- European study
Glad to share the publication of the manuscript “A first-in-human study of Tenalisib (RP6530), a dual PI3K δ/γ inhibitor, in patients with relapsed/refractory hematologic malignancies: results from the European study” in Clinical Lymphoma Myeloma and Leukemia